Charly Travers

Technology is rapidly changing how people get their food, and restaurants are adapting.

Every diversified portfolio needs global exposure. We dive into some of the benefits and risks involved with international stocks.

Coach's stock rose 4% Tuesday on fiscal-year earnings that were not as bad as the market feared. International markets, particularly China, continue to perform. North America remains weak, but we remain hopeful that the imminent launch of Creative Director Stuart Vevers' new collection will invigorate the brand.

After two quarters of losses, it was nice to see for-profit educator Bridgepoint Education back in the black. Is this company finally on the right track?

Arcos Dorados' financial performance continues to go in the wrong direction. With management again lowering its guidance for the year, it's time for MDP to part ways with this Latin American fast-food chain.

Coach's stock rose 4% Tuesday on fiscal-year earnings that were not as bad as the market feared. International markets, particularly China, continue to perform well. North America remains weak, but we remain hopeful that the imminent launch of Stuart Vevers' new collection will invigorate the brand.

The market frequently gets it wrong with even the highest-quality companies. Make sure your portfolio is prepared to take advantage of these opportunities when they arise.

Patient Exelixis shareholders are on the verge of knowing whether or not Cometriq is beneficial to prostate cancer patients with respect to improving overall survival and lessening pain. After the company's Q2 earnings report, MDP is still awaiting those trial results sometime this year.

The company's growth this year may not be as robust as once hoped, but keep your eye on the moves it's making to ensure that it remains the top dog in organic and natural foods.

Baidu's collection of highly desirable digital assets is paying off with consistent revenue growth over 50%. The company has proven that it can thrive in a mobile world, and now that it has added maps, streaming video, and app distribution to its product portfolio, there's no end in sight to its growth.

In the fable of the tortoise and the hare, Bladex would be the tortoise. This conservative Latin American bank quietly goes about its business of providing trade financing to corporations and other financial institutions. Income-loving Fools can sleep well at night with this bank and enjoy its tasty 4.7% yield.

You know it's a good quarter for Microsoft when its Bing search engine delivered 40% growth in ad revenue. Satya Nadella has a clear vision for Microsoft as a provider of cloud-based services, and in that role, the company is thriving.

Halfway through 2014, Intel is seeing strong demand across its most important segments, including chips for desktop PCs and servers. The company raised its financial guidance for the year. After reviewing the results, MDP is raising its Buy and Sell Around prices.

Exelixis' drug development partner Roche reported a successful Phase 3 clinical trial for the combination of cobimetinib and Zelboraf in the treatment of metastatic melanoma. However, until Roche releases the full data set, investors will be left guessing on some key points.

Exelixis' drug development partner Roche reported a successful Phase 3 clinical trial for the combination of cobimetinib and Zelboraf in the treatment of metastatic melanoma. However, until Roche releases the full data set, investors will be left guessing on some key points.

Charly scans the Fool universe for great businesses with share prices that have disappointed so far this year. Best-of-breed companies almost always bounce back with long-term market-beating performance.

Coach's financial performance continues to deteriorate as the company prepares for the launch of Creative Director Stuart Vevers' new products. Management is making the right strategic decisions for the long-term health of the business, but the short-term costs are steep.